

PUBLIKATIONSLISTE

Priv.Doz.Dr.med. Birgit Grünberger

44 Originalarbeiten
4 letters
2 case reports
1 review
3 Buchbeiträge
64 publizierte Abstracts

Krankenhaus der Barmherzigen Brüder
Medizinische Abteilung
Johannes-von-Gott-Platz 1/1
1020 Wien

Tel : +43-1-21121/2100
e-mail: birgit.gruenberger@bbwien.at

PAPERS

1. CETUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH UNRESECTABLE ADVANCED OR METASTATIC BILIARY TRACT CANCER: A PHASE 2 STUDY

Birgit Gruenberger, Johannes Schueller, Ute Heubrandtner, Fritz Wrba, Dietmar Tamandl, Klaus Kaczirek, Rudolf Roka, Sandra Freimann-Pircher, and Thomas Gruenberger
Lancet Oncology, 2010 Dec;11(12):1142-8. Epub 2010 Nov 9

IF: 14,470

2. IMPORTANCE OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN POTENTIALLY CURABLE COLORECTAL CANCER LIVER METASTASES
Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D and Gruenberger
BMC Cancer, 2008 Apr 25;8:120.

IF: 3,087

3. BEVACIZUMAB, CAPECITABINE AND OXALIPLATIN AS NEOADJUVANT THERAPY FOR PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER

Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski, Herbst F, Gruenberger T
J Clin Oncol. 2008 Apr 10;26(11):1830-5

IF: 17,157

4. USING BEVACIZUMAB AND CETUXIMAB BEFORE LIVER SURGERY
Gruenberger B, Gruenberger T
Current Colorectal Cancer Reports 2008

5. ASSESSMENT OF THE ROLE OF HEPATITIS C, HELICOBACTER PYLORI AND AUTOIMMUNITY IN MALT LYMPHOMA OF THE OCULAR ADNEXE IN 45 AUSTRIAN PATIENTS

Gruenberger B, Woehrer S, Troch M, Hauff W, Lukas J, Streubel B, Muellauer L, Chott A, Raderer M.
Acta Oncol. 2007 Oct 22;1-5

IF: 2,739

6. PALLIATIVE CHEMOTHERAPY FOR RECURRENT AND METASTATIC ESOPHAGEAL CANCER

Grünberger B, Raderer M, Schmidinger M, Hejna M.
Anticancer Res. 2007 Jul-Aug;27(4C):2705-14. Review

7. ANTIBIOTIC TREATMENT IS NOT EFFECTIV IN PATIENTS INFECTED WITH HELICOBATCER PYLORI SUFFERING FROM EXTRAGASTRIC MUCOSE-ASSOCIATED LYMPHIOD TISSUE LYMPHOMA

Gruenberger B, Woehrer S, Streubel B, Formanek M, Petkov V, Puespoek A, Haefner M, Hejna M, Jaeger U, Chott A and Raderer
J Clin Oncol 2006, 24 (9):1370-1375

IF: 17,157

8. "BLIND" ANTIBIOTIC TREATMENT TARGETING CHLAMYDIA IS NOT EFFECTIVE IN PATIENTS WITH MALT LYMPHOMA OF THE OCULAR ADNEXA
Grünberger B, Hauff W, Lukas J, Wöhrer S, Zielinski Z, Streubel B, Chott A and Raderer M
Ann Oncol 2006,17: 484–487

IF: 4,935

9. HER-2 NEU PROTEIN EXPRESSION IN COLORECTAL CANCER
Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch and Wrba F
BMC Cancer 2006, 6; 123

IF: 3,087

10. SIDE EFFECTS DURING CHEMOTHERAPY PREDICT TUMOR RESPONSE IN ADVANCED COLORECTAL CANCER
B. Schuell, T. Gruenberger, G.V. Kornek, N. Dworan, D. Depisch, F. Lang, B. Schneeweiss and W. Scheithauer
Br J Cancer 2005; 93, 744 – 748

IF: 4,846

11. EFFECTIVE COMBINATION CHEMOTHERAPY WITH BIMONTHLY DOCETAXEL AND CISPLATIN ± HEMATOPOETIC GROWTH FACTOR SUPPORT IN PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER
Schüll B, Kornek GV, Schmid K, Raderer M, Hejna M, Lenauer A, Depisch D, Lang F and Scheithauer W
Oncology 2003; 65(3):211-7

IF: 1,336

12. CAPECITABINE AS SALVAGE THERAPY FOR BREAST CANCER PATIENTS WITH EXTENSIVE LIVER METASTASES AND ASSOCIATED IMPAIRMENT OF LIVER FUNCTION
Schüll B, Scheithauer W, Kornek GV
Onkologie 2003 Dec; 26(6):578-80; Case report

13. IDIOSYNCRATIC REACTION AFTER OXALIPLATIN: CIRCUMVENTION BY USE OF A CONTINUOUS INFUSIONAL ADMINISTRATION SCHEDULE
Schüll B, Kornek GV, Scheithauer W
Ann Oncol 2001; 12:1653-1654; Case report

14. RALTITREXED UND OXALIPLATIN BEIM KOLOREKTALEN KARZINOM: IN VITRO UND IN VIVO UNTERSUCHUNG EINER SYNERGISTISCH WIRKSAMEN ZYTOSTATIKAKOMBINATION
Schüll B, Scheithauer W
Acta medica austriaca 2002;29:124-131

IF: +1,5 (Dissertation)

15. SECOND LINE TREATMENT OF ADVANCED COLORECTAL CANCER WITH A BIWEEKLY OXALIPLATIN PLUS IRINOTECAN COMBINATION THERAPY
Schüll B, Kornek G.V., Schmid K, Raderer M, Ulrich-Pur H, Fiebiger W, Schneeweiss B, Lenauer A, Depisch D and Scheithauer W
Onkologie 2002;25:358-362

IF: 1,545

16. HEPATIC ARTERIAL CHEMOTHERAPY FOR LIVER METASTASES FROM COLORECTAL CANCER : TREATMENT RESULTS, LIMITATIONS & FUTURE ASPECTS

Schüll B, Scheithauer W
Eur Surg 2002;34:344-346

17. [SINUSOIDAL OBSTRUCTION SYNDROME IMPAIRS LONG-TERM OUTCOME OF COLORECTAL LIVER METASTASES TREATED WITH RESECTION AFTER NEOADJUVANT CHEMOTHERAPY.](#)

Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, **Gruenberger B**, Gruenberger T.

Ann Surg Oncol. 2011 Feb;18(2):421-30. Epub 2010 Sep 16.

IF= 4,130

18. [PLASMA DISPOSITION OF CAPECITABINE AND ITS METABOLITES 5'DFCR AND 5'DFUR IN A STANDARD AND DOSE-INTENSIFIED MONOTHERAPY REGIMEN.](#)

Czejka M, Schueller J, Farkouh A, **Gruenberger B**, Scheithauer W.

Cancer Chemother Pharmacol. 2011 Mar;67(3):613-9. Epub 2010 May 22.

IF= 2,654

19. [BEVACIZUMAB IMPROVES PATHOLOGICAL RESPONSE OF COLORECTAL CANCER LIVER METASTASES TREATED WITH XELOX/FOLFOX.](#)

Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, **Gruenberger B**, Gruenberger T.

Ann Surg Oncol. 2010 Aug;17(8):2059-65. Epub 2010 Feb 23.

IF= 4,130

20. [LIVER RESECTION REMAINS A SAFE PROCEDURE AFTER NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB: A CASE-CONTROLLED STUDY.](#)

Tamandl D, **Gruenberger B**, Klinger M, Herberger B, Kaczirek K, Fleischmann E, Gruenberger T.

Ann Surg. 2010 Jul;252(1):124-30.

IF= 7,9

21. [PHARMACOKINETICS OF IRINOTECAN IN COMBINATION WITH BIWEEKLY CETUXIMAB IN PATIENTS WITH ADVANCED COLORECTAL CANCER.](#)

Czejka M, **Gruenberger B**, Kiss A, Farkouh A, Schueller J.

Anticancer Res. 2010 Jun;30(6):2355-60.

IF= 1,414

22. THROMBOSPONDIN-1: A UNIQUE MARKER TO IDENTIFY IN VITRO PLATELET ACTIVATION WHEN MONITORING IN VIVO PROCESSES

P. Starlinger, H. P. Moll, A. Assinger, C. Nemeth, K. Hoetzenecker, **B. Gruenberger**, T. Gruenberger, I. Kuehrer, S. F. Schoppmann, M. Gnant and C. Brostjan

Journal of Thrombosis and Haemostasis, 2010 Aug;8(8):1809-19. doi: 10.1111/j.1538-7836.2010.03908.x. Epub 2010 May 12.

IF=6.069

23. LYMPH NODE RATIO AFTER CURATIVE SURGERY AFTER INTRAHEPATIC CHOLANGIOCARCINOMA

Tamandl D, Kaczirek K, **Gruenberger B**, Koelblinger C, Maresch J, Jakesz R and Gruenberger T

British Journal of Surgery 2009; 96: 919-35

IF: 4,921

24. SYSTEMIC BEVACIZUMAB (AVASTIN) THERAPY FOR EXUDATIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. THE BEAT-AMD-STUDY

K E Schmid-Kubista, I Krebs, **B Gruenberger**, F Zeiler, J Schueller and S Binder

Br.J. Ophthalmology 2009;93;914-919

IF:2,859

25. BEVACIZUMAB PROTECTS AGAINST SINUSOIDAL OBSTRUCTION SYNDROME AND DOES NOT INCREASE RESPONSE RATE IN NEOADJUVANT XELOX/FOLFOX THERAPY OF COLORECTAL CANCER LIVER METASTASES

Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, **Gruenberger B**, Gruenberger T.

Eur J Surg Oncol. 2009 May;35(5):515-20

IF: 2,491

26. SURGERY AFTER NEOADJUVANT CHEMOTHERAPY FOR COLORECTAL LIVER METASTASES IS SAFE AND FEASIBLE IN EDERLY PATIENTS

Tamandl D, **Gruenberger B**, Herberger B, Kaczirek K, Gruenberger T.

J Surg Oncol. 2009 Oct 1;100(5):364-71.

IF: 2,478

27. INFLUENCE OF HEPATIC RESECTIN MARGIN ON RECURRENCE AND SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA

Tamandl D, Herberger B, **Gruenberger B**, Puhalla H, Klinger M, Gruenberger T

Ann Surg Oncol. 2008 Oct;15(10):2787-94

IF: 3,898

28. PATTERNS OF HEPATOTOXICITY AFTER CHEMOTHERAPY FOR COLORECTAL CANCER LIVER METASTASES

Kandutsch S, Klinger M, Hacker S, Wrba F, **Gruenberger B**, Gruenberger T

Eur J Surg Oncol 2008, Feb 11

IF: 2,491

29. NEOADJUVANT TREATMENT OF COLORECTAL CANCER WITH BEVACIZUMAB: THE PERIOPERATIVE ANGIOGENIC BALANCE IS SENSITIVE TO SYSTEMIC THROMOSPONDIN-1 LEVELS

Brostjan C, Gebhardt K, **Gruenberger B**, Steinrueck C, Zommer H, Freudenthaler H, Roka S and Gruenberger T

Clin Cancer Res 2008 Apr 1;14(7):2065-74

IF: 6,488

30. SELECTIVE RESECTION OF COLORECTAL LIVER METASTASES

Tamandl D, **Gruenberger B**, Herberger B, Schoppmann S, Bodingbauer M, Schindl M, Puhalla H, Fleischmann E, Schima W, Jakesz R, Laengle F, Gruenberger T

Eur J Surg Oncol 2007; 33:174-82

31. ADEQUATE PREOPERATIVE STAGING RARELY LEADS TO A CHANGE OF INTRAOPERATIVE STRATEGY IN PATIENTS UNDERGOING SURGERY FOR COLORECTAL CANCER LIVER METASTASES D.

Tamandl, B. Herberger, **B. Gruenberger**, S. Schoppmann, H. Puhalla, M. Schindl, W. Schima, R. Jakesz, Th. Gruenberger
Surgery 2008, May;143(5):648-57.

IF: 3,389

32. ACTIVATED MAMMALIAN TARGET OF RAPAMYCIN IS AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH BILIARY TRACT ADENOCARCINOMA

Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, **Gruenberger B**, Gruenberger T, Pirker R, Filipits M
Clin Cancer Res. 2007 Aug 15;13(16):4795-9

IF: 6,488

33. NEOADJUVANT THERAPY WITH BEVACIZUMAB

Gruenberger T, **Gruenberger B** and Scheithauer W
J Clin Oncol 2006, 24: 2592-3, letter

34. BEVACIZUMAB IS ACTIVE IN MALIGNANT EFFUSION

Pichelmayer O, **Gruenberger B**, Zielinski C, Raderer M.
Ann Oncol 2006; 17; 1853, letter

35. INTERDISCIPLINARY MANAGEMENT OF COLORECTAL CANCER LIVER METASTASES Th.

Grünberger, **B. Grünberger**, A. Becherer, J. Kettenbach, K. Dieckmann, W. Schima Eur Surg 2006; 38: 107-11

36. TREATMENT AND OUTCOME OF INTRAHEPATIC CHOLANGIOCELLULAR CARCINOMA

Puhalla H, **Schüll B**, Pokorny H, Kornek GV, Scheithauer W, Gruenberger T Am J Surg 2005, 189/2;173-7

IF: 2,605

37. CHANGES IN LIVER SURGERY FOR COLORECTAL CANCER LIVER METASTASES UNDER NEOADJUVANT TREATMENT STRATEGIES

Gruenberger T, **Schüll B**, Puhalla H, Schwanzer E, Bodingbauer M, Laengle F, Kornek G, Scheithauer W
Eur Surg 2004, 36(5), 317-21

38. MITOMYCIN C IN COMBINATION WITH CAPECITABINE OR BIWEEKLY HIGH DOSE GEMCITABINE IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER: A RANDOMIZED PHASE II TRIAL

Kornek GV, **Schüll B**, Laengle F, Gruenberger T, Penz M, Karall K, Depisch D, Lang F, Scheithauer W
Ann Oncol 2004 Mar;15(3):478-83

IF: 4,935

39. BIWEEKLY HIGH-DOSE GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA: A RANDOMIZED PHASE II TRIAL

Scheithauer W, **Schüll B**, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV
Ann Oncol
2003 Jan;14(1):97-104

IF: 4,935

40. RANDOMIZED MULTICENTER PHASE II TRIAL OF TWO DIFFERENT SCHEDULES OF CAPECITABINE PLUS OXALIPLATIN AS FIRST LINE TREATMENT IN ADVANCED COLORECTAL CANCER

Scheithauer W, Kornek GV, Raderer M, **Schüll B**, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A and Depisch D
J Clin Oncol 2003 Apr 1;21(7):1307-12

IF: 17,157

41. IRINOTECAN PLUS RALTITREXED VERSUS RALTITREXED ALONE IN PATIENTS WITH GEMCITABINE-PRETREATED ADVANCED PANCREATIC ADENOCARCINOMA

Ulrich-Pur H, Raderer M, Kornek GV, **Schüll B**, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F and Scheithauer W
Br J Cancer 2003 Apr 22;88(8):1180-4

IF: 4,846

42. SECOND-LINE TREATMENT OF ADVANCED GASTRIC CANCER WITH OXALIPLATIN PLUS RALTITREXED

Schmid K, Kornek GV, **Schüll B**, Raderer M, Lenauer A, Depisch D, Lang F, Scheithauer W
Onkologie 2003 Jun; 26(3):255-8.

IF: 1,545

43. INTERMITTENT WEEKLY HIGH-DOSE CAPECITABINE IN COMBINATION WITH OXALIPLATIN: A PHASE I/II STUDY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER

Scheithauer W, Kornek GV, Raderer M, **Schüll B**, Schmid K, Längle F and Huber H
Ann Oncol 2002 Oct;13(10):1583-9

IF: 4,935

44. EFFECTIVE TREATMENT OF OXALIPLATIN-INDUCED CUMULATIVE POLYNEUROPATHY WITH ALPHA-LIPOIC ACID

Gedlicka C, Scheithauer W, **Schüll B**, Kornek GV
J Clin Oncol 2002 Aug 1;20(15):3359-61, letter

45. EFFECTIVE COMBINATION CHEMOTHERAPY WITH PACLITAXEL AND CISPLATIN WITH OR WITHOUT G-CSF AND/OR ERYTHROPOIETIN IN PATIENTS WITH ADVANCED GASTRIC CANCER

Kornek GV, Raderer M, **Schüll B**, Fiebiger W, Gedlicka C, Lenauer A, Depisch D, Schneeweiss B, Lang F, Scheithauer W
Brit J Cancer 2002; 86:1858-1863

IF: 4.459

46. MITOXANTRON AND CISPLATIN IN RECURRENT AND/OR METASTATIC SALIVARY GLAND MALIGNANCIES

Gedlicka C, **Schüll B**, Formanek M, Kornfehl J, Burian M, Knerer B, Selzer E, Scheithauer W, Kornek GV

Anti-Cancer Drugs 2002 Jun; 13(5):491-5

47. RANDOMIZED MULTICENTER PHASE II TRIAL OF OXALIPLATIN PLUS IRINOTECAN VERSUS RALTITREXED AS FIRST-LINE TREATMENT IN ADVANCED COLORECTAL CANCER

Scheithauer W, Kornek GV, Raderer M, Fiebiger W, Gedlicka C, Schüll B, Brugger S, Lang F, Lenauer A, and Depisch
J Clin Oncology 2002; 20:165-172,2002

IF: 17,157

48. TREATMENT OF ADVANCED BREAST CANCER WITH DOCETAXEL AND GEMCITABINE ± HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR

Kornek GV, Haider K, Kwasny W, Raderer M, Schüll B, Payrits T, Depisch D, Kovats E, Lang F, Scheithauer W
Clinical Cancer Research 2002 May; 8(5):1051-6

IF: 6,488

49. TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA WITH BIWEEKLY HIGH-DOSE GEMCITABINE

Ulrich-Pur H, Kornek GV, Fiebiger W, Schüll B, Raderer M, Scheithauer W
Oncology 2001 Jun;60(4):313-315

IF: 1,336

50. SECOND LINE TREATMENT WITH OXALIPLATIN + RALTITREXED IN PATIENTS WITH ADVANCED COLORECTAL CANCER FAILING FLUOROPYRIMIDINE/LEUCOVORIN BASED CHEMOTHERAPY

Scheithauer W, Kornek GV, Schüll B, Ulrich-Pur H, Fiebiger W, Raderer M, Lang F, Schneeweiss B, Lenauer A, Depisch D
Ann Oncol 2001; 12:709-714

IF: 4,935

51. IMPACT OF HEMOGLOBIN LEVEL AND USE OF RECOMBINANT ERYTHROPOETIN ON EFFICACY PREOPERATIVE CHEMO-RADIATION THERAPY FOR SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

Glaser CM, Millesi W, Kornek GV, Lang S, Schüll B, Watzinger F, Selzer E, Lavey RS
Int J Radiat Oncol Biol Phys 2001 Jul 1;50(3):705-15

IF: 4,639

52. OXALIPLATIN-INDUCED FEVER AND RELEASE OF IL-6

Ulrich-Pur H, Fiebiger WC, Schüll B, Kornek GV, Scheithauer W, Raderer M
Oncology 2000 Sep;59(3):187-9, letter

DISSERTATION

RALTITREXED UND OXALIPLATIN BEIM KOLOREKTALEN KARZINOM: IN VITRO UND IN VIVO UNTERSUCHUNGEN EINER SYNERGISTISCH WIRKSAMEN ZYTOSTATIKAKOMBINATION

Betreuung und Erstbegutachter: Ao. Univ. Prof. Dr. Werner Scheithauer
Begutachter: Ao. Univ. Prof. Dr. Gerhard Hamilton

BUCHBEITRÄGE

1. CHIRURSCHE THERAPIE COLORECTALER LEBERMETASTASEN

Gruenberger Th, **Gruenberger B**

In: Tumorchirurgie – Strategien und Standards für die Praxis, Springer Verlag 2007; in press

2. COLORECTAL CANCER LIVER METASTASES: NEOADJUVANT THERAPY WITH BEVACIZUMAB

Gruenberger Th, **Gruenberger B**

In: Methods of Cancer Diagnosis, Therapy and Prognosis; Springer Verlag 2007; in press

3. SYSTEMISCHE CHEMOTHERAPIE BEI KOLOREKTALEN LEBERMETASTASEN: NEOADJUVANT, ADJUVANT UND PALLIATIV

Grünberger B.

In: Therapiemanagement von Lebermetastasen von Gastrointestinalen Tumoren; Uni-Med Verlag; in press

PREISE

1. BEST ABSTRACT

Frühjahrstagung 2008 der österr. Gesellschaft für Hämatologie und Onkologie

Für: Progression-free survival in a phase II study of perioperative Bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer **Grünberger B** et al.

ABSTRACTS & POSTER & VORTRÄGE

1. IFOSFAMIDE AND NOVANTRON IN THE TREATMENT OF RECURRENT AND/OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK (HNSCC)

Schüll B, Glaser C, Millesi W, Ulrich-Pur H, Kornfehl J, Burian M, Formanek M, Toth J, KornekGV

Frühjahrstagung 2000 der Österreichischen Gesellschaft für Hämatologie und Onkologie

2. R-HuERYTHROPOETIN TREATMENT INCREASES EFFICACY OF NEO-ADJUVANT RADIOCHEMOTHERAPY AND IMPROVES CANCER FREE SURVIVAL OF PATIENTS WITH ORAL SQUAMOUS CELL CARCINOMA
Glaser C, Millesi W, Wanschitz F, **Schüll B**, Lang S, Leitha T, Kornek GV
ACSO Vol.18:1543 Atlanta 15-18 Mai 1999

3. R-HuERYTHROPOETIN SUPPLY INCREASES EFFICACY OF NEOADJUVANT RADIOCHEMOTHERAPIE IN PATIENTS WITH ORAL SQUAMOUS CARCINOMA
Glaser C, Millesi W, Gössweiner S, Leitha T, **Schüll B**, Ewers R, Lang S
14th International Conference on oral and Maxillofacial Surgery in Washington DC, USA 24
29 April 1999

4. MULTICENTER PHASE II TRIAL OF DOSE-FRACTIONATED IRINOTECAN IN PATIENTS WITH ADVANCED COLORECTAL CANCER FAILING OXALIPLATIN-BASED FIRST-LINE COMBINATION CHEMOTHERAPY
Fiebiger W, Ulrich-Pur H, Kornek GV, Raderer M, Gedlicka G, **Schüll B**, Depisch D, Lang F, Pidlich J, Scheithauer W
Frühjahrstagung 2001 der Österr. Gesellschaft für Hämatologie und Onkologie, Pörschach

5. GEMCITABINE PLUS CAPECITABINE: AN EFFECTIVE DRUG COMBINATION FOR ADVANCED PANCREATIC ADENOCARCINOMA
Ulrich-Pur H, Kornek GV, Raderer M, Fiebiger W, Gedlicka G, **Schüll B**, Depisch D, Lang F, Schneeweiss B, Scheithauer W
Frühjahrstagung 2001 der Österr. Gesellschaft für Hämatologie und Onkologie, Pörschach

6. TREATMENT OF ADVANCED GASTRIC CANCER WITH PACLITAXEL AND CISPLATIN + HEMATOPOETIC GROWTH FACTOR SUPPORT
Penz M, Raderer M, Kornek GV, Fiebiger W, Ulrich-Pur H, **Schüll B**, Scheithauer W
Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaften für Hämatologie und Onkologie; Graz 21-25 Oktober 2000

7. PALLIATIVE CHEMOTHERAPIE DES KOLOREKATLEN KARZINOMS MIT TOMUDEX UND OXALIPLATIN
Schüll B, Kornek GV, Ulrich-Pur H, Penz M, Fiebiger W, Raderer M, Haider K, Kwasny W, Depisch D, Scheithauer W
Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaft für Hämatologie und Onkologie; Graz 21-25 Oktober 2000

8. TREATMENT OF ADVANCED BREAST CANCER WITH DOCETAXEL AND GEMCITABINE + HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
Kornek GV, Fiebiger W, Raderer M, Gedlicka C, **Schüll B**, Haider K, Kwasny W, Depisch D, Scheithauer W
Frühjahrstagung 2001 der Österr. Gesellschaft für Hämatologie und Onkologie, Pörschach

9. IRINOTECAN PLUS OXALIPLATIN IN ADVANCED COLORECTAL CANCER: A RANDOMIZED PHASE II STUDY
Ulrich-Pur H, Kornek GV, Raderer M, Fiebiger C, **Schüll B**, Scheithauer W
Third International Conference: Perspectives in Colorectal Cancer, Dublin, June 7-9. 2001

10. RANDOMIZED MULTICENTER PHASE II TRIAL OF OXALIPLATIN PLUS IRINOTECAN VERSUS RALTITREXED AS FIRST-LINE TREATMENT IN ADVANCED COLORECTAL CANCER

Schüll B, Kornek GV, Raderer M, Fiebiger W, Gedlicka G, Ulrich-Pur H, Brugger S, Schneeweiss B, Lang F, Lenauer A, Depisch D, Scheithauer W
Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaft für Hämatologie und Onkologie 2001; Mannheim 30 Sept- 3 Okt

11.DOCETAXEL PLUS CISPLATIN ± GRANULOCYTE COLONY-STIMULATING FACTOR AND/OR ERYTHROPOIETIN IN PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER

Schüll B, Kornek GV, Schmid K, Raderer M, Ulrich-Pur H, Haider K, Kwasny W, Depisch D, Lang F, Hejna M, Scheithauer W
Frühjahrstagung 2002 der ÖGHO; Linz 25-27 April 2002

12.BIWEEKLY HIGH-DOSE GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH METASTATIC ADENOCARCINOM: A RANDOMIZED PHASE II TRIAL

Scheithauer W, **Schüll B**, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek G
Symposium on gastrointestinal, liver and pancreatic cancer, Venice, June 6-8,2002

13.INTERMITTENT WEEKLY HIGH-DOSE CAPECITABINE IN COMBINATION WITH OXALIPLATIN: A PHASE I/II STUDY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER

Kornek GV, **Schüll B**, Schmid K, Raderer M, Längle F, Scheithauer W
Symposium on gastrointestinal, liver and pancreatic cancer, Venice, June 6-8,2002

14.BIWEEKLY HIGH DOSE GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA: A RANDOMIZED MULTICENTER PHASE II TRIAL

Kornek GV, **Schüll B**, Ulrich-Pur H, Raderer M, Schmid K, Schneeweiss B, Lang F, Haider K, Kwasny W, Depisch D, Scheithauer
12th International Congress on Anti-Cancer Treatment, Febr. 4th-7th, 2002

15.INTERMITTENT WEEKLY HIGH-DOSE CAPECITABINE IN COMBINATION WITH OXALIPLATIN: A PHASE I/II STUDY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER

Scheithauer W, Kornek GV, Raderer M, **Schüll B**, Schmid K, Längle F, Huber H
12th International Congress on Anti-Cancer Treatment, Febr. 4-7, 2002

16.TREATMENT OF ADVANCED BREAST CANCER WITH DOCETAXEL AND GEMCITABINE ± HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR Haider K, Kornek GV, Fiebiger W, Raderer M, Gedlicka C, **Schüll B**, Kwasny W, Depisch D, Scheithauer W.

18. Jahrestagung der österr. Gesellschaft für Senologie, Toscana Congress Gmunden, 10.-13.Oktober 2001

17.GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA

Scheithauer W, **Schüll B**, Ulrich-Pur H, Schmid K, Raderer M, Lang F, Haider K, Kwasny W
38 annual meeting, ASCO, 18-21 May,2002

18. BIWEEKLY DOCETAXEL PLUS CISPLATIN +/- HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND/ OR ERYTHROPOETIN IN PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER

Schüll B, Kornek GV, Raderer M, Dworan N, Haider K, Kwasny K, Depisch D, Lang F, Hejna M, Scheithauer W
ÖGHO 2002, München

19. PALLIATIVE CHEMOTHERAPIE MIT ORALEM ETOPOSID IN VORBEHANDELTEN PATIENTEN MIT FORTGESCHRITTENEM KOPF-HALS MALIGNOM

Gedlicka G, **Schüll B**, Formanek M, Kornfehl J, Ramberger P, Burian M, Kornek GV
46. Österr. HNO-Kongreß 2002

20. MITOMYCIN C IN COMBINATION WITH CAPTECITABINE OR BIWEEKLY HIGH DOSE GEMCITABINE IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER: PRELIMINARY RESULTS OF PARALLEL PHASE II TRIAL

Kornek GV, Schmid K, **Schüll B**, Raderer M, Kwasny W, Haider K, Depisch D, Friedrich L, Scheithauer W
27th ESMO Congress 18-22 Oct 2002, Nice, France

21. GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA

Scheithauer W, **Schüll B**, Ulrich Pur H, Schmid K, Raderer M, Lang F, Haider K, Kwasny W
38th ASCO 2002, Orlando, Florida

22. MITOMYCIN C IN COMBINATION WITH CAPTECITABINE OR BIWEEKLY HIGH DOSE GEMCITABINE IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER

Scheithauer W, **Schüll B**, Dworan N, Laengle F, Gruenberger T, Penz M, Haider K, Depisch D, Lang F, Kornek G
ASCO Proceedings 2003; 22:1059

23. NEOADJUVANT CHEMOTHERAPY FOR RESECTABLE COLORECTAL LIVER METASTASES: IMPACT ON LIVER RESECTION

Gruenberger T, **Schuell B**, Kornek G, Scheithauer W
HBP 2004, 6/Suppl 1, 109 (Abstract 1186)

24. INTRAHEPATIC CHOLANGIOCELLULAR CARCINOMA: POSSIBLE BENEFIT OF A MULTIDISCIPLINARY APPROACH

Gruenberger T, Puhalla H, **Schuell B**, Kornek GV, Scheithauer W
HPB 2004, 6/Suppl 1 (abstract 1187)

25. NEOADJUVANT CHEMOTHERAPY FOR RESECTABLE COLORECTAL LIVER METASTASES: IMPACT ON LIVER RESECTION AND SURVIVAL

Gruenberger T, **Schuell B**, Kornek GV, Scheithauer W
Proceedings Am Soc Clin Oncol 2004; 23,270 (Abstract 3598)

26. NEOADJUVANT CHEMOTHERAPY FOR RESECTABLE COLORECTAL LIVER METASTASES: IMPACT ON LIVER RESECTION AND SURVIVAL

Gruenberger T, **Schuell B**, Kornek GV, Scheithauer W
Posterpräsentation Gastrointestinal Cancer-Meeting Barcelona, 17-19.6.2004

27. DAS INTRAHEPATISCHE CHOLANGIOZELLULÄRE KARZINOM: VORTEILE INTER MULTIDISZIPLINÄREN THERAPIE

Puhalla H, **Schüll B**, Längle F, Kornek GV, Scheithauer W, Gruenberger T
European Surgery 2004; 36/Suppl 198,62

28. DO SIDE EFFECTS DURING CHEMOTHERAPY PREDICT TUMOR RESPONSE IN
ADVANCED COLORECTAL CARCINOMA?
Schüll B., Grünberger T, Kornek GV, Dworan N, Scheithauer W
Ann. Oncology 2004; 15 (Suppl. 3), ii90
29. DO SIDE EFFECTS DURING CHEMOTHERAPY PREDICT TUMOR RESPONSE IN
ADVANCED COLORECTAL CARCINOMA?
Schüll B., Grünberger T, Kornek GV, Dworan N, Scheithauer W
Onkologie 2004; 27(Suppl. 3) 195
30. NEOADJUVANT CHEMOTHERAPY IN PRIMARY RESECTABLE COLORECTAL
CANCER LIVER METASTASES Th.
Gruenberger, **B. Schuell**, G. Kornek, W. Scheithauer
Ann. Oncology 2004, 15 (Suppl. 3), ii97
31. ELDERLY PATIENTS DO BENEFIT FROM OXALIPLATIN-BASED NEOADJUVANT
CHEMOTHERAPY IN RESECTABLE COLORECTAL CANCER LIVER METASTASES
Th. Gruenberger, **B. Schuell**, G. Kornek, W. Scheithauer
Proc. Am. Soc. Clinical Oncology 2005; 23/16S,271s(Abstract 3601)
32. HER 2/NEU RECEPTOR EXPRESSION IN COLORECTAL CANCER
B. Schuell, T. Gruenberger, W. Scheithauer, Ch. Zielinski, F. Wrba
World of Gastrointestinal Cancer, Barcelona, June 2005
33. ANTIBIOTIC TREATMENT IS NOT EFFECTIVE IN PATIENTS WITH
EXTRAGASTRIC MALT LYMPHOMA INFECTED WITH HELICOBACTER PYLORI
B. Grünberger, S. Wöhrer, B. Streubel, M. Formanek, V. Petkov, A. Püspök, M. Häfner,
M. Hejna, U. Jäger, A. Chott, M. Raderer
DÖGHO 2005 Hannover
34. VEGF-A EXPRESSION IN PERITONEAL OR PLEURAL EFFUSIONS WITH OR
WITHOUT MALIGNANCIES
B. Gruenberger, O. Pichlmayer, P. Valent, Th. Gruenberger, M. Krauth, R. Bauer, C.
Zielinski, M. Raderer
DÖGHO 2006
35. VEGF-A EXPRESSION IN PERITONEAL OR PLEURAL EFFUSIONS WITH OR
WITHOUT MALIGNANCIES
B. Gruenberger, O. Pichlmayer, P. Valent, Th. Gruenberger, M. Krauth, R. Bauer, C.
Zielinski, M. Raderer
Ann Oncology 2006; 17(Supp 9): ix68
36. BEVACIZUMAB PLUS XELOX AS NEOADJUVANT THERAPY FOR PATIENTS
WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER
Th. Gruenberger, D. Tamandl, F. Herbst, W. Scheithauer, C. Zielinski, **B. Gruenberger**
Ann Oncology 2006; 17(Supp 9): ix128
37. PROLONGED RECURRENCE-FREE SURVIVAL AFTER NEOADJUVANT
CHEMOTHERAPY FOR COLORECTAL CANCER LIVER METASTASES
Gruenberger Th, **Gruenberger B.**, Tamandl D, Scheithauer W
HPB 2006; 8(Supp 2): 125

- 38.IMPACT OF LYMPHANGIOGENESIS IN COLORECTAL LIVER METASTASES
S. Schoppmann, A. Fenzl, D. Tamandl, M. Bodingbauer, M. Schindl, H. Puhalla, **B. Gruenberger**, B. Teleky, T. Gruenberger, F. Längle
Ann Oncology 2006; 17(Supp 6): vi33
- 39.NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB IN POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER
B. Gruenberger, W. Scheithauer, D. Tamandl, H. Puhalla, G. Kornek, C. Zielinski, Th. Gruenberger
Ann Oncology 2006; 17(Supp 6): vi39
- 40.SAFE SURGERY FOR COLORECTAL CACER LIVER METASTASES USING MODERN DISSECTION TECHNIQUES
D. Tamandl, **B. Gruenberger**, B. Herberger, S. Schoppmann, M. Bodingbauer, E. Fleischmann, W. Schima, R. Jakesz, F. Laengle, Th. Gruenberger
Ann Oncology 2006; 17(Supp 6): vi57
- 41.RESECTION OF COLORECTAL LIVER METASTASES UNDER THE ASPECT OF MODERN DISSECTION TECHNIQUES
D. Tamandl, **B. Gruenberger**, B. Herberger, S. Schoppmann, M. Bodingbauer, R. Jakesz, F. Längle, Th. Gruenberger
European Surgery 2006; 38/Suppl 209, 47
- 42.IMPACT OF LYMPHANGIOGENESIS IN COLORECTAL LIVER METASTASES
SF Schoppmann, A. Fenzl, D. Tamandl, M. Bodingbauer, M. Schindl, B. Herberger, E. Schwanzer, H. Puhalla, **B. Gruenberger**, B. Teleky, Th. Gruenberger, F. Längle
European Surgery 2006; 38/Suppl 209, 18
- 43.NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB IN POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER
B. Gruenberger, W. Scheithauer, D. Tamandl, H. Puhalla, G. Kornek, C. Zielinski, T. Gruenberger
JCO 2006; 24: 157 (suppl, Abstract 3546)
- 44.BEVACIZUMAB PLUS XELOX AS NEOADJUVANT THERAPY FOR PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER
T. Gruenberger, D. Tamandl, H. Puhalla, W. Scheithauer, C. Zielinski, **B. Gruenberger**
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement),2007: 4064
- 45.EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB IN PATIENTS WITH RESECTABLE COLORCTAL CANCER LIVER METASTASES
B. Gruenberger, W. Scheithauer, D. Tamandl, C. Zielinski, J. Schueller, T. Gruenberger
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4060
- 46.EFFECTIVITY OF NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB IN PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORCTAL CANCER
B. Gruenberger, W. Scheithauer, D. Tamandl, C. Zielinski, J. Schueller, T. Gruenberger
Ann Oncology, 2007, 18 (Supplement 7): vii 76

47. NEOADJUVANT BEVACIZUMAB PLUS XELOX IS FEASIBLE IN PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER RECEIVING SYNCHRONOUS RESECTION

B. Gruenberger, W. Scheithauer, D. Tamandl, C. Zielinski, J. Schueller, T. Gruenberger
EJC 2007, 5 (4, Supplement): 255

48. INFLUENCE OF BEVACIZUMAB (BEV) ON PHARMACOKINETICS (PK) AND METABOLISM OF CAPECITABINE (CAPE) IN METASTATIC COLORECTAL CANCER (MCRC)

J. Schueller, M. Czejka, A. Farkouh, K. Aigner, E. Krexner and **B. Gruenberger**
Gastrointestinal Cancer Symposium, 2008, 423

49. DOES DOSE ESCALATION OF CAPECITABINE (CAPE) INFLUENCE ITS METABOLIC CONVERSION IN METASTATIC COLORECTAL CANCER PATIENTS (MCRC)?

J. Schueller, M. Czejka, A. Farkouh, D. Ettliger, E. Krexner, **B. Gruenberger**
Gastrointestinal Cancer Symposium, 2008, 433

50. PROGRESSION-FREE SURVIVAL IN A PHASE II STUDY OF PERIOPERATIVE BEVACIZUMAB PLUS XELOX IN PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER

B. Grünberger, K. Kaczirek, J. Schüller, M. Bergmann, C. Zielinski, K. Aigner, T. Grünberger
Frühjahrstagung 2008 der österr. Gesellschaft für Hämatologie und Onkologie

51. SYSTEMIC BEVACIZUMAB THERAPY FOR EXUDATIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (BEAT-AMD-STUDY).

Schmid-Kubista KE, Krebs I, **Gruenberger B**, Schueller J, Binder S
Annual ARVO Meeting 27.4.2008, Fort Lauderdale, USA, Poster 304

52. OXALIPLATIN, IRINOTECAN AND CETUXIMAB IN ADVANCED GASTRIC CANCER: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL (AGMT GASTRIC-2)

E. Woell, R. Greil, W. Eisterer, M. Fridrik, **B. Grünberger**, K. Gattringer, B. Mayrbäurl, G. Russ, J. Thaler
J Clin Oncology 26: 2008 (suppl, Abstract 15587)

53. EFFICACY RESULTS OF CETUXIMAB PLUS GEMCITABINE-OXALIPLATIN (GEMOX) IN PATIENTS WITH ADVANCED OR METASTATIC CHOLANGIOCARCINOMA: A SINGLE CENTRE PHASE II STUDY.

B. Gruenberger, J. Schueller, K. Kaczirek, M. Bergmann, W. Klose, M. Bischof, G. Schernthaner, T. Gruenberger
J Clin Oncology 26: 2008 (suppl, Abstract 4568)

54. PROGRESSION-FREE SURVIVAL IN A PHASE II STUDY OF PERIOPERATIVE BEVACIZUMAB PLUS XELOX IN PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER.

T. Gruenberger, K. Kaczirek, M. Bergmann, C. C. Zielinski, **B. Gruenberger**
J Clin Oncology 26: 2008 (suppl, Abstract 4073)

55. DOXORUBICIN PHARMACOKINETICS FOLLOWING TWO DIFFERENT LIPOSOMAL FORMULATIONS (CAELYX VS MYOCET) IN ADVANCED BREAST CANCER PATIENTS

Schueller J, Czejka M, Krexner E, Aigner K, **Gruenberger B**

56.K-RAS STATUS AND RESPONSE IN PATIENTS WITH ADVANCED OR METASTATIC CHOLANGIOCARCINOMA TREATED WITH CETUXIMAB PLUS GEMCITABINE-OXALIPLATIN (GEMOX): A SINGLE CENTER PHASE II STUDY

B. Gruenberger, Schueller J, Tamandl D, Kaczirek K, Schernthaner G, Gruenberger T
J Clin Oncology 27:15s, 2009 (suppl, Abstract 4586)

57.OXALIPLATIN, IRINOTECAN AND CETUXIMAB IN ADVANCED GASTRIC CANCER. FIRST EFFICACY RESULTS OF A MULTICENTER PHASE II TRIAL (AGMT GASTRIC-2) OF THE ARBEITSGEMEINSCHAFT MEDIKAMENTOESE TUMORTHERAPIE (AGMT).

E. Woell, R. Greil, W. Eisterer, M. Fridrik, **B. Grünberger**, A. Zabernigg, B. Mayrbäurl, G. Russ, J. Thaler

J Clin Oncology , 27:15s (2009) (suppl, Abstract 4538)

58.SECONDARY RESECTABILITY IN PATIENTS WITH ADVANCED OR METASTATIC CHOLANGIOCARCINOMA TREATED WITH CETUXIMAB PLUS GEMCITABINE-OXALIPLATIN (GEMOX): A SINGLE CENTER PHASE II STUDY;

B Grünberger, J. Schüller, D. Tamandl, K. Kaczirek, G. Schernthaner, T Grünberger;
European Surgery 2009; 144/Suppl 230/09

59.SECONDARY RESECTABILITY IN PATIENTS WITH ADVANCED OR METASTATIC CHOLANGIOCARCINOMA TREATED WITH CETUXIMAB PLUS GEMCITABINE-OXALIPLATIN (GEMOX): A SINGLE CENTER PHASE II STUDY;

B Grünberger, J. Schüller, D. Tamandl, K. Kaczirek, G. Schernthaner, T Grünberger;
ACO-ASSO JAHRESTAGUNG, POSTER, 09.10.2009, ST WOLFGANG

60.INFLUENCE OF CETUXIMAB APPLIED AS BIWEEKLY INFUSION ON THE PLASMA DISPOSITION OF CPT 11 AND ITS METABOLITES IN ADVANCED COLORECTAL CANCER

J Schueller,, **B. Gruenberger**

Eco Esmo Berlin 09

61.ASSOCIATION OF VEGF FEEDBACK PRODUCTION IN BEVACIZUMAB THERAPY WITH SYSTEMIC RESPONSE.

P. Starlinger, T. Maier, D. Schauer, C. Nemeth, L. Alidzanovic, **B. Gruenberger**, T. Gruenberger, C. Brostjan

J Clin Oncol 28:15s, 2010 (suppl; abstr 3056)

62.INFLUENCE OF THE K-RAS STATUS ON OUTCOME IN CHOLANGIOCARCINOMA.

D. Niedersuess-Beke, T. Gruenberger, D. Tamandl, F. Wrba, H. Feichtinger, K. Kaczirek, J. G. Meran, **B. Gruenberger**

J Clin Oncol 28, 2010 (suppl; abstr e21076)

63.PRE- AND POSTOPERATIVE CHEMOTHERAPY INCLUDING BEVACIZUMAB IN POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER: A MULTICENTER, SINGLE-ARM PHASE II TRIAL—RESULTS OF ASSO LM1.

T. Gruenberger, F. Laengle, J. Thaler, W. Eisterer, D. Tamandl, B. Herberger, A. Lenauer, **B. Gruenberger**

J Clin Oncol 28, 2010 (suppl; abstr e14032)

64.INFLUENCE OF THE K-RAS STATUS ON OUTCOME IN CHOLANGIOCARCINOMA.

Birgit Gruenberger, Dora Niedersuess-Beke, Dietmar Tamandl, Fritz Wrba, Klaus Kaczirek, Johannes Meran and Thomas Gruenberger

World Congress of GI Cancer, Barcelona, July 2010, P-0082

65. TOLERABILITY OF NEOADJUVANT CHEMOTHERAPY WITH GEMCITABINE PLUS CISPLATIN IN ELDERLY (OLDER THAN AGE 65) PATIENTS (PTS) WITH MUSCLE-INVASIVE UROTHELIAL CANCER

D. Niedersuess-Beke, **B. Gruenberger**, T. Puntus, W. Bauer, M. Lamche, P. Schramek, J. G. Meran

J Clin Oncol 29: 2011 (suppl 7; abstr 296)

66. INFLUENCE OF KRAS STATUS OF COLORECTAL CANCER LIVER METASTASES IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB PRIOR LIVER RESECTION

Stefan Stremitzer, Judith Maresch, Thomas Aschacher, Brigitte Wolf, Fritz Wrba, Thomas Gruenberger, **Birgit Gruenberger**

Frühjahrstagung ÖGHO, Pörtschach, Mai 2011-05-29

67. INFLUENCE OF KRAS STATUS OF COLORECTAL CANCER LIVER METASTASES IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB PRIOR LIVER RESECTION

Stefan Stremitzer, Judith Maresch, Thomas Aschacher, Brigitte Wolf, Fritz Wrba, Thomas Gruenberger, **Birgit Gruenberger**

Annual Meeting ASCO 2011, Chicago, June 2011

SONSTIGE ARBEITEN & FORTBILDUNGSVORTRÄGE

1. HEPATOTOXIZITÄT

Schüll B, Scheithauer W

Krebshilfe 4/02

2. MULTIMODALE LEBERMETASTASENTHERAPIE

Schüll B, Scheithauer W, Grünberger T

Chirurgie 4/02

3. ASCO NEWS: CHEMOTHERAPIE DES FORTGESCHRITTENEN KOLOREKTALKARZINOMS

Grünberger B

Jatros 9/05

4. PHASE II XELOX PLUS IRESSA

Schüll B, Vortrag

POST ASCO Update 2003, Salzburg Juni 2003

5. XELODA: DIE ORALE TUMORTHERAPIE: EMPFEHLUNGEN FÜR DIE PRAXIS

Schüll B, Vortrag

Das kolorektale Karzinom – ASCO 2004 Update, Pötsching, 4. Nov. 2004

6. DERZEITIGE PALLIATIVE THERAPIEOPTIONEN BEIM METASTASIIERTEN KOLOREKTALEN KARZINOM

Schüll B, Vortrag

Fortbildungsveranstaltung Oberpullendorf, 13.Okt. 2004

7. INNOVATIVE THERAPIEN BEIM KOLOREKTALKARZINOM: ADJUVANTE THERAPIE

Grünberger B., Vortrag

Fortbildungsveranstaltung Zwettl, 22.November 2005

8. THERAPIE DES KOLOREKTALKARZINOMS

Grünberger B., Vortrag

Fortbildungsveranstaltung Radstadt, 6.Jänner 2006

9. NEUE THERAPIEANSÄTZE BEIM METASTASIIERTEN KOLONKARZINOM

Grünberger B., Vortrag

Fortbildungsveranstaltung Kaprun, März 2006

10. IST DAS METASTASIIERTE KOLOREKTALE KARZINOM HEILBAR?

Grünberger B., Vortrag

47. Österreichischer Chirurgenkongress, Juni 2006

11. INTERDISZIPLINÄREN MANAGEMENT VON LEBERTUMOREN UND LEBEROP WORKSHOP 2006, AKH-WIEN

Kursleitung: Onkologische Sicht

Grünberger B.

12. AVASTIN – anti VEGF – COLORECTAL CANCER

Grünberger B., Vortrag

5th International Symposium on Cancer research and Therapy (Tokio, November 2006)

13. THERAPIE DES METASTASIIERTEN KOLONKARZINOMS

Grünberger B., Vortrag

Fortbildungsveranstaltung Laa/Thaya, Dezember 2006

14. TARCEVA BEIM METASTASIIERTEN PANKREASKARZINOM: PRAKTISCHE ASPEKTE UND NEBENWIRKUNGSMANAGEMENT

Grünberger B., Vortrag

Fortbildungsveranstaltung, Wien, März 2007

15. THERAPIE DES METASTASIIERTEN KOLOREKTALKARZINOM – EIN ÜBERBLICK

Grünberger B., Vortrag

Interdisziplinäres Symposium, Wien, Mai 2007

16. DAS METASTASIIERTE CRC – INNOVATIVE THERAPIEN AUS ONKOLOGISCHER SICHT

Grünberger B., Vortrag

Fortbildungsveranstaltung, Oberwart, Oktober 2007

17. NEOADJUVANTE CHEMOTHERAPIE BEI KOLOREKTALEN LEBERMETASTASEN

Grünberger B.

Krebshilfe, Heft 1/2008

18. „HÄUFIGE TUMOREN II - MAMMAKARZINOM“ (DIABETESSPEZIFISCHE ÄTIOLOGIE, FRÜHERKENNUNG, INTERDISZIPLINÄRES MANAGEMENT)

Grünberger B.

19. „NEOADJUVANTE CHEMOTHERAPIE BEI KOLOREKTALEN LEBERMETASTASEN“
Grünberger B, Vortrag
Workshop Deliver Excellence, Wien, September 2009
20. „THERAPIE DES METASTASIIERTEN KOLOREKTALKARZINOMS – EIN UPDATE“
Grünberger B, Vortrag
CNM Symposium, 17.Sep 2009, Kaiserpavillon
21. „RATIONALE DER NEOADJUVANTEN THERAPIE UND LEVEL I EVIDENCE BEI KOLOREKTALEN LEBERMETASTASEN“
Grünberger B, Vortrag
Individualisierte Krebstherapie, Aco-Asso Jahrestagung, 9.10.2009, St Wolfgang
22. „G-LUCAS TRIAL“
Grünberger B, Vortrag
CRCR-Experten-Meeting – „K-ras and Beyond“, Wien, 27.2.1010
23. EXPERTENFORUM – XELODA IM ADJUVANTEN SETTING
Grünberger B, Teilnahme
Wien, 28.05.2010
24. EXPERTENMEETING: NEUES THERAPIE-KONZEPT BEI MALIGNEN ASZITES
Grünberger B, Teilnahme
Wien, 9.9.2010
25. SYSTEMISCHE THERAPIE DES NIERENZELLKARZINOMS
Grünberger B, Vortrag
5.Urologisch-Onkologisches Symposium, BHB Wien, 16.10.2010
26. UPDATE MCRC 2010 – RECENT DEVELOPMENTS
Grünberger B, Vortrag
3.VEGF SYMPOSIUM, Mayerling, 22.10.2010
27. „G-LUCAS TRIAL“
Grünberger B, Vortrag
ABC SG-Meeting – Saalfelden, 07.11.1010
28. ÜBERBLICK ZUR PALLIATIVEN THERAPIE DES KOLOREKTALKARZINOMS
Grünberger B
Krebshilfe Heft 5:2010
29. SYSTEMISCHE CHEMOTHERAPIE CHOLANGIOCELLULÄRES KARZINOM
Grünberger B, Vortrag
ÖGGH – Gastroenterologische onkologische Diskussion „Cholangiocelluläres Karzinom“
22.1.2011, Wien
30. MALIGNEN TUMOREN DER GALLENBLASE / GALLENGÄNGE
Grünberger B, Vortrag
DESO Kurs, Diagnostik und Therapie von Patienten/innen mit gastrointestinalen Tumoren
13. - 14. Mai 2011 Innsbruck